Genomic Testing and Toxicity Shape Advanced Prostate Cancer Care
Experts detail how next-generation sequencing, radiation for oligoprogression, and managing treatment access and side effects are refining management of metastatic prostate cancer.
Oncology experts stress that managing advanced prostate cancer requires multidisciplinary collaboration to balance efficacy, toxicity, and patient preference. Treatment decisions for metastatic castration-sensitive prostate cancer are increasingly guided by genomic testing and novel radiation approaches, with care teams integrating radiation oncology, nuclear medicine, and palliative specialists to improve survival and quality of life.
Radiation's evolving role in metastatic disease
Radiation therapy, including stereotactic body radiotherapy, is seeing expanded use for bone metastases and cases of oligoprogression. Evidence from trials like STAMPEDE supports a survival benefit for prostate-directed radiotherapy in patients with low-volume metastatic disease. For patients whose prostate-specific antigen is rising but with only a limited number of lesions visible on PET imaging, radiation may offer disease control. Palliative radiation also remains a key tool for managing pain or preventing fractures from symptomatic bone metastases.
Genomic testing guides systemic therapy sequencing
Somatic next-generation sequencing results are now critical for selecting systemic therapies. Medical oncologist Benjamin A. Gartrell often initiates androgen deprivation therapy while awaiting these results before choosing a specific androgen receptor pathway inhibitor. "I try to wait on making ARPI decisions for most patients until I get next-generation sequencing," Gartrell stated. The presence of specific genetic alterations, such as in BRCA or other homologous recombination repair genes, can direct use of PARP inhibitor combinations approved based on recent phase 3 trials.
| Trial Name | Drug Combination | Patient Population | Median rPFS (Combination vs Control) | Hazard Ratio (95% CI) |
|---|---|---|---|---|
| AMPLITUDE | niraparib + abiraterone/prednisone | BRCA2-mutated mCSPC | Not estimable vs 26 months | 0.46 (0.32-0.66) |
| TALAPRO-3 | talazoparib + enzalutamide | HRR-altered mCSPC | Not reached vs 45.8 months | 0.481 (0.357-0.647) |
| CAPItello-281 | capivasertib + abiraterone/prednisone | PTEN-deficient mCSPC | 33.2 months vs 25.7 months | 0.81 (0.66-0.98) |
This genomic-directed strategy creates sequencing challenges, as upfront use of potent androgen receptor pathway inhibitors changes the treatment landscape when resistance develops. Ilan J. Safir favors considering effective treatments earlier because some patients may never reach later lines of therapy.
Toxicity and access considerations
Logistical hurdles and side effect profiles are major factors in clinical decisions. Shaheer Ahmad Khan, a medical oncologist at Northwell Health, cautions that requirements for hospitalization, monitoring, and caregiver support can create unequal access to therapies. Gartrell highlighted practical challenges, such as administering radioligand therapy to patients in small or multigenerational homes. The need for bone-protective agents like zoledronic acid or denosumab in castration-resistant disease adds another layer to management. Experts express interest in newer agents like alpha-emitting radioligands and T-cell engagers but emphasize that outpatient feasibility and lower toxicity burdens will be key to their practical use. Continued integration of genomic testing and novel radioligand therapies into multidisciplinary care pathways aims to address these complex needs for metastatic prostate cancer patients.
